Developing drugs in cancer-related bone pain

•About 75% of patients with bone involvement is interested by pain.•Cancer-related bone pain has both a nociceptive and a neuropathic component.•Cancer-related bone pain could be treated with analgesics drugs, or prevented with “bone therapy”.•Moreover, new biological drugs are in development for th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Critical reviews in oncology/hematology Jg. 119; S. 66 - 74
Hauptverfasser: Lucchesi, Maurizio, Lanzetta, Gaetano, Antonuzzo, Andrea, Rozzi, Antonio, Sardi, Iacopo, Favre, Claudio, Ripamonti, Carla Ida, Santini, Daniele, Armento, Grazia
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Netherlands Elsevier B.V 01.11.2017
Schlagworte:
Analgesics, Opioid - pharmacology
Analgesics, Opioid - therapeutic use
Bone metastases
Bone Neoplasms - physiopathology
Bone Neoplasms - secondary
Cancer pain
Cancer Pain - drug therapy
Humans
Nerve growth factor
Opioids
Quality of Life
Randomized Controlled Trials as Topic
RANK
RANK-L
Cancer pain
Nerve growth factor
RANK
Bone metastases
RANK-L
Opioids
ISSN:1040-8428, 1879-0461, 1879-0461
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•About 75% of patients with bone involvement is interested by pain.•Cancer-related bone pain has both a nociceptive and a neuropathic component.•Cancer-related bone pain could be treated with analgesics drugs, or prevented with “bone therapy”.•Moreover, new biological drugs are in development for this topic. Cancer-related bone pain is a frequent and important key problem for metastatic patients that may reduce quality of life, with related limitations in daily activities and morbidity. Often traditional approach to pain may fail given the complex pathophysiology of this phenomenon. The aim of this review is to describe promising therapies for cancer-related bone pain, from the pathophysiology to the clinical trials currently ongoing. Moreover, any new evidence for better approach to cancer-related bone pain with the traditional drugs is also considered. In clinical practice opioids remain the most important pharmacologic treatment for severe pain related to bone cancer. Regard developing drugs, anti-NGF and anti-TrkA are the most investigated new drug in this setting, but a future role in clinical practice is still uncertain.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1040-8428
1879-0461
1879-0461
DOI:10.1016/j.critrevonc.2017.08.005